Trans-fatty acids killing 5.4 lakh a year: Govt

NEW DELHI : High intake of trans-fatty acids increases the risk of coronary heart disease, Union health minister Mansukh Mandaviya told Lok Sabha on Friday.

In a written reply to a Parliament question, Mandaviya said industrially produced trans-fat is commonly found in packaged foods, baked goods, cooking oil and spreads. “Approximately 5,40,000 deaths each year are estimated to be attributed to the intake of industrially produced trans-fatty acids,” he said. The health minister said that high trans-fat intake may increase the risk of death from any cause by 34%, and coronary heart disease deaths by 28%.
“This is likely due to the effect on lipid levels: trans-fat increases LDL (low-density lipoprotein) or bad cholesterol levels while lowering HDL (high-density lipoprotein) or good cholesterol levels. According to the World Health Organisation, 4.6% of coronary heart disease deaths in India may be related to trans-fatty acid intake ( 0.5% of energy intake),” Mandaviya said.

Food Safety Standard Authority of India (FSSAI) has implemented best-practice policy as specified by WHO to gradually reduce the trans-fats consumption in India.

In this regard, the health minister explained, FSSAI has notified the Food Safety and Standards (Prohibition and Restrictions on Sales) Second Amendment Regulations, 2021, on February 2, 2020, and Food Safety and Standards (Food Products Standards and Food Additives) Tenth Amendment Regulations, 2020, on December 29, 2020, to reduce the maximum limit of industrial trans-fatty acids to not more than 2% by weight in edible oils, fats and food products in which edible oils and fats are used as an ingredient. “These amendments came into effect from January 1, 2022. The changes introduced are in line with recommendations of the World Health Organisation,” he added.

Related Posts

  • Pharma
  • July 26, 2024
  • 110 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 105 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD